Results 221 to 230 of about 86,750 (278)

Analytical Characterization, Pharmacokinetics, Safety, and Preliminary Immunogenicity of GNR-062, an Agalsidase Beta Biosimilar Candidate, in Healthy Male Volunteers. [PDF]

open access: yesBioTech (Basel)
Lyagoskin I   +8 more
europepmc   +1 more source

VCAM-1 as a biomarker of early cardiac phenotypic changes in Fabry disease. [PDF]

open access: yesBMC Cardiovasc Disord
Lino DODC   +8 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Fabry's disease

Journal of the Neurological Sciences, 2014
Fabry's disease is an X-linked lysosomal storage disorder caused by abnormalities in the GLA gene, which leads to a deficiency in α-galactosidase A. The abnormal accumulation of glycosphingolipids, primarily globotriaosylceramide, manifests as serious and progressive impairment of renal and cardiac functions.
Rima, El-Abassi   +2 more
openaire   +2 more sources

Charles Fabry

Applied Optics, 1973
The opening session of the 1968 International Ozone Symposium in Monaco was a centenary year ribute to Charles Fabry. This paper is a record of the three speeches made during the session.
J, Lecomte, A, Arnulf, E, Vassy
openaire   +2 more sources

Fabry disease

Journal of Echocardiography, 2017
Fabry disease resulting from a deficiency of α-galactosidase A leads to the accumulation of globotriaosylceramide in various organs. Because the disease is an X-linked recessive disorder, males tend to develop more symptoms and more severe symptoms than females.
Toshinori Yuasa   +10 more
openaire   +2 more sources

Fabry disease

Current Opinion in Neurology, 2011
This review discusses the literature on Fabry disease mainly in the domain of neurology with special attention to recent advancement.Fabry neuropathy is known as a length-dependent peripheral neuropathy affecting mainly the small myelinated (Aδ) fibers and unmyelinated (C) fibers.
openaire   +3 more sources

Home - About - Disclaimer - Privacy